GlaxoSmithKline has announced that they will begin Phase 3 development of their anaemia drug, daprodustat. The drug is an oral …
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board

